Filing Flows › Taysha Gene Therapies (TSHA) › Q2 2025 › vs Q1 2025
Taysha Gene Therapies (TSHA) Q2 2025 vs Q1 2025 (quarter over quarter)
Taysha Gene Therapies's revenue fell $316K (-14%) from $2.3M in Q1 2025 to $2.0M in Q2 2025.
Taysha Gene Therapies, Q2 2025: revenue $2.0M (+79% year over year), net loss $26.9M, operating cash flow −$20.2M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q2 2025 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.0M | $2.3M | −$316K | -14% |
| Net loss | $26.9M | $21.5M | $5.4M | +25% |
| Costs & expenses | $28.9M | $23.8M | $5.0M | +21% |
| Operating costs | $28.7M | $23.7M | $5.0M | +21% |
| Interest & other, net | $129K | $108K | $21K | +19% |
| Research & development | $20.1M | $15.6M | $4.6M | +29% |
| General & admin | $8.6M | $8.2M | $440K | +5% |
| Operating cash sources | $26.9M | $21.5M | $5.4M | +25% |
| Depreciation | $300K | $283K | $17K | +6% |
| Share-based compensation | $3.2M | $3.3M | −$104K | -3% |
| Working capital & other | $3.2M | −$4.1M | $7.3M | — |
| Cash used in operations | $20.2M | $22.0M | −$1.8M | -8% |
| Net loss absorbed | $26.9M | $21.5M | $5.4M | +25% |
Questions
How much did Taysha Gene Therapies's revenue grow quarter over quarter in Q2 2025?
Taysha Gene Therapies's revenue fell $316K (-14%) from $2.3M in Q1 2025 to $2.0M in Q2 2025.